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Background: In low-resource settings, where abortion is highly restricted and self-induced abortions are common,
access to post-abortion care (PAC) services, especially treatment of incomplete terminations, is a priority. Standard
post-abortion care has involved surgical intervention but can be hard to access in these areas. Misoprostol provides
an alternative to surgical intervention that could increase access to abortion care. We sought to gather additional
evidence regarding the efficacy of 400 mcg of sublingual misoprostol vs. standard surgical care for treatment of
incomplete abortion in the environments where need for economical non-surgical treatments may be most useful.
Methods: A total of 860 women received either sublingual misoprostol or standard surgical care for treatment of
incomplete abortion in a multi-site randomized trial. Women with confirmed incomplete abortion, defined as past
or present history of vaginal bleeding during pregnancy and an open cervical os, were eligible to participate.
Participants returned for follow-up one week later to confirm clinical status. If abortion was incomplete at that time,
women were offered an additional follow-up visit or immediate surgical evacuation.
Results: Both misoprostol and surgical evacuation are highly effective treatments for incomplete abortion
(misoprostol: 94.4%, surgical: 100.0%). Misoprostol treatment resulted in a somewhat lower chance of success than
standard surgical practice (RR = 0.90; 95% CI: 0.89-0.92). Both tolerability of side effects and women’s satisfaction
were similar in the two study arms.
Conclusion: Misoprostol, much easier to provide than surgery in low-resource environments, can be used safely,
successfully, and satisfactorily for treatment of incomplete abortion. Focus should shift to program implementation,
including task-shifting the provision of post-abortion care to mid- and low- level providers, training and assurance
of drug availability.
Trial registration: This study has been registered at clinicaltrials.gov as NCT00466999 and NCT01539408
Keywords: Misoprostol, Manual vacuum aspiration (MVA), Incomplete abortion, Post-abortion care (PAC)Background
Complications of pregnancy failure (spontaneous or
induced abortion) are a major cause of maternal morbid-
ity and mortality, particularly in low-resource settings
where abortion is highly restricted and self-induced
abortions are common [1]. In these countries access to
post-abortion care (PAC) services, especially treatment
of incomplete terminations, is a priority.* Correspondence: adiop@gynuity.org
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reproduction in any medium, provided the orStandard post-abortion care has involved surgical
intervention, such as dilatation and curettage (D&C) or
vacuum aspiration (manual or electric), to complete
uterine evacuation and prevent infection. However, in
low-resource areas, surgical methods can be difficult to
access due to a scarcity of trained providers, sterile sur-
gical facilities, and/or inadequate transportation to
higher level centers where surgical procedures are most
often performed. Misoprostol, a drug which is easy to
store and requiring no surgical skills to administer, pro-
vides an alternative to surgical intervention that couldl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to task-shifting efforts by enabling lower level providers
to manage post-abortion care. This could be particularly
helpful in places with limited human resources.
Misoprostol has been established as an effective alter-
native to surgical care; randomized trials comparing 600
mcg of oral misoprostol to manual vacuum aspiration
(MVA) for treatment of incomplete abortion found
comparable efficacy (91.0% - 99% for misoprostol vs.
91.5% - 100% for MVA) and equal or higher levels of
satisfaction among women assigned to the misoprostol
arms [2-5]. An extensive review concluded that 600
mcg of oral misoprostol should be recommended for
treatment of incomplete abortion [6]. An additional ran-
domized study established 400 mcg of sublingual miso-
prostol as equally effective as the 600 mcg oral regimen
with similar side effects and participant satisfaction [7].
Another study confirmed similar efficacy rates for 400
mcg sublingual misoprostol and MVA [8]. Using 400
mcg misoprostol instead of 600 mcg might mean sig-
nificant cost reduction in treatment, particularly import-
ant in places where misoprostol is expensive relative to
income levels.
We sought to gather additional evidence regarding 400
mcg of sublingual misoprostol vs. standard surgical care
for treatment of incomplete abortion in the environ-
ments where need for economical non-surgical treat-
ments may be most useful.
Methods
Data from one multi-site (Mauritania, Niger and Senegal)
and two country-level (Burkina Faso and Nigeria)
randomized trials comparing sublingual misoprostol to
standard surgical care for treatment of incomplete
abortion were combined. All women presenting to one
of the study sites (located in Guédiawaye, Senegal;
Nouakchott, Mauritania; Niamey, Niger; Ibadan, Nigeria;
and Ouagadougou and Bobo Dioulasso, Burkina Faso),
who lived or worked within 1 hour travel time, who
had a confirmed incomplete abortion (spontaneous or
induced), and who met the study criteria were invited to
participate. An eligible incomplete abortion was defined
as past or present history of vaginal bleeding during
pregnancy and an open cervical os (if ultrasound not
used) or evidence of incomplete abortion with substantial
debris in uterus, if ultrasound used. Requirements for
eligibility included no contraindications to the study drug,
uterine size no larger than that consistent with 12 week
gestation at time of presentation for care, no signs
of severe infection, no hemodynamic disturbances,
general good health, and willingness to provide contact
information for purposes of follow-up. Women who
were suspected of having an ectopic pregnancy were not
eligible for the study. All participants would have beenadvised to have a surgical evacuation of the uterus if
misoprostol were not available. Similar study protocols
were approved by ethical review boards in each countrya
and all participants gave written, informed consent.
The trials included in this paper are registered as two
separate studies on clinicaltrials.gov (NCT00466999 and
NCT01539408).
Participants were randomly assigned to either one
dose of 400 mcg of sublingual misoprostol (200 mcg tab-
let × 2) (CytotecW, Pfizer, USA) or a surgical evacuation
of the uterus following standard practice at each hospital
(MVA or D&C). (The multicenter sites were randomized
together and the two country-level sites were rando-
mized individually). Women assigned to the misoprostol
group took the pills at the hospital and were instructed
to hold the pills under their tongues for 30 minutes and
then swallow any remaining tablet fragments. They were
then discharged at the provider’s discretion. Women
assigned to the surgical arm received immediate surgical
evacuations at the study hospital. Analgesics and anti-
biotics for participants receiving surgical treatment were
given per each facility’s clinical norms; no anesthesia was
used during the procedures.
Participants were asked to return to the clinic 1 week
later to confirm clinical status. In the event of continued
heavy bleeding, an enlarged uterus, or any suspicion of
an ectopic pregnancy, the woman was referred for ultra-
sound and follow-up care. If continued incomplete abor-
tion was determined by clinical exam or by ultrasound
in either of the study arms, women were given the op-
tion of an immediate surgical evacuation or returning
for additional follow-up 1 week later to see if expulsion
had occurred spontaneously. If, after the second follow-
up visit, abortion was not complete, a surgical comple-
tion was performed. All women were advised that they
could return to the study site at any time if complica-
tions arose, or if they had questions. Care throughout
the study was provided by clinicians at all levels. In all
sites except Mauritania and Nigeria, care was provided
by midwives or nurses. In both these sites, care was
mostly given by physicians although nurses and mid-
wives were involved in counseling and follow-up. Only
some clinicians at the Burkina Faso sites had previous
experience with misoprostol for treatment of incomplete
abortion [4].
A sample size of 390 (195 per arm) was needed to detect
a 5% one-sided difference between surgical (assumed to be
98% effective) and sublingual misoprostol with a 95% con-
fidence interval and 80% power. Data on demographics,
method outcome, side effects, and women’s satisfaction
with the treatment were combined from the 6 sites and
analyzed using relative risk, chi-square, and independent
t-tests as appropriate. Use of ultrasound and any neces-
sary interventions were also documented and evaluated.
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analyses were conducted with Stata software (Version 11,
College Station, TX).
Results
A total of 860 women were enrolled in the study be-
tween May 2007 and October 2010 (Figure 1). Partici-
pants were randomly assigned to 1 of the 2 study
groups: 480 to misoprostol and 380 to standard surgical
treatment. (In Burkina Faso, the misoprostol arm was
oversampled with a 2:1 allocation to gain additional ex-
perience in using this method). Twenty-one women
were lost to follow-up before study completion and
therefore are only included in the demographic analyses.
We examined participant characteristics including age,
parity, education, marital status, and abortion type
(spontaneous or induced) (Table 1).
Treatment of incomplete abortion with both methods
resulted in complete uterine evacuation for more than 9
out of 10 women. Efficacy with the misoprostol was
slightly lower: 94.4% of the women who received miso-
prostol and 100% of the women who received surgical
intervention had successful evacuations (RR = 0.90; 95%
CI: 0.88-0.92) (Table 2). The majority of the successful
evacuations were confirmed at the first follow-up (91.8%
(393/428) in the misoprostol arm and 99.4% (360/362)
in the surgical arm; data not shown). There was vari-
ation in success with misoprostol by site, with comple-
tion rates ranging from 88.7% in Niger to 97.6% in
Burkina Faso, where providers had previous experience
using misoprostol for treatment of incomplete abortion.
At the beginning of the study at three of the sites
(Senegal, Niger, and Mauritania), many failures with
misoprostol (the new treatment) were recorded; successAnalyzed (n= 465) 
Excluded from analysis (n = 15) 
Lost to follow-up (n =15) 
Discontinued intervention (n = 0) 
Analy
Follow
Allocated to misoprostol (n=480) 
Received intervention (n= 465) Alloca
Randomized 
Figure 1 Study flowchart.rates increased considerably after the first month of mis-
oprostol exposure as providers became more familiar
with the method. At these sites, complete uterine evacu-
ation was recorded for 76.2-86.2% of participants receiv-
ing misoprostol in the first month of recruitment and
increased to 92.3-95.7% during the remaining months
(data not shown). In Niger, all but 1 failure occurred in
the first 3 months of recruitment (data not shown). And
in Senegal, all but 1 failure occurred in the first 5 weeks
of recruitment (data not shown).
Use of ultrasound to determine outcome was more
likely to occur with women in the misoprostol arm than
with those in the surgical arm (Table 2). In Senegal,
ultrasound use for misoprostol participants was required
by the local ethics committee and was used in over 81%
of the cases to confirm outcome. (Use decreased from
90% in the first half to 52% in the second half of the
study). Among the other 4 sites, ultrasound use was also
significantly higher in the misoprostol group (27.1% vs.
17.5%, p < 0.01).
Severity of side effects was similar for participants in
the 2 study arms (Table 3). Slightly more women in the
misoprostol group than in the surgical group reported
that side effects were tolerable or easily tolerable (miso-
prostol: 77.5%, surgical: 71.0%; p = 0.02); however, very
few women in either study group reported side effects as
severe or very severe (misoprostol: 7.7%, surgical: 5.0%).
Although reports of pain and/or cramps were signifi-
cantly greater in the misoprostol group (54.8% vs. 24.4%,
p < 0.001), reports of tolerability of pain were greater in
that group as well with 92.2% of the misoprostol group
and 85.3% of the surgical group reporting that pain was
“tolerable” or “very tolerable” (p < 0.01). Finally, where
reported, almost all women in both groups reported thatLost to follow-up (n =6) 
Discontinued intervention (n = 0) 
Analyzed (n = 374) 
Excluded from analysis (n = 6) sis
-Up
Allocated to surgical treatment (n = 380) 
Received intervention (n= 374) tion
(n = 860) 






n = 480 n = 380
Age in years:
mean ± SD (range)
28.1 ± 7.2 (13-48)a 28.7 ± 7.3 (14-46)b 0.19
Education level: % (n) 0.63
No education 30.6 (118/385) 28.3 (80/283)
Primary 24.9 (96/385) 23.7 (67/283)
Secondary 30.9 (119/385) 31.1 (88/283)
Tertiary 13.5 (52/385) 17.0 (48/283)
Marital status: % (n) 0.20
Single 11.5 (55/478) 8.3 (31/372)
Married 87.0 (416/478) 90.9 (338/372)
Divorced 1.5 (7/478) 0.8 (3/372)
Parity: mean ± SD
(range)





Spontaneous 94.0 (440/468) 95.9 (349/364)
Induced 6.0 (28/468) 4.1 (15/364)
* Denominators vary due to response rate for each question.
a n = 478.
b n = 375.
c n = 479.





Complete abortion 94.4 (439)






Burkina Faso 97.6 (206/21
Ultrasound used to evaluate successb: % (n) 39.1 (167/42
Senegalc 81.1 (77/95
Other 4 sites 27.1 (90/332
Women who made an unscheduled visitd 2.9 (13/452
Women who called the providere 6.0 (27/448
a21 women from the Niger site were lost to follow-up: 15 in the misoprostol arm an
bUltrasound data is not available for 74 women: 38 in the misoprostol arm and 36 i
cSenegal was required by their IRB to use ultrasound in evaluating outcome.
d3 women in the misoprostol arm made 2 unscheduled visits; all others made only
e4 women in the misoprostol arm called twice; all other callers called once.
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cult” and that the bleeding was “acceptable” or “very
acceptable.”
Satisfaction with the procedure was very high in both
study groups, with almost all women “satisfied” or “very
satisfied” (Table 4). However, significantly more women
in the misoprostol than in the surgical arm would select
their method again (97.6% vs. 87.8%, p < 0.001) and
would recommend their method to a friend (97.6% vs.
85.8%, p < 0.001).
Discussion
These data present yet another example of how miso-
prostol can be successfully incorporated into standard
post-abortion care services [2-4,6,7]. The difference in
side effects between the two groups is also comparable
to what has been shown in similar studies [4,5,8]. Of
note, the success rates for misoprostol at three of the
sites were much higher after the first month of use. This
“learning curve” for the clinicians offering misoprostol
provides an excellent example of what may occur when
misoprostol is first made available as a method of uter-
ine evacuation in new settings.
The majority of surgical interventions in our study
were initiated by women’s concerns over the amount
and/or duration of bleeding; it is certainly possible that
at least some of the interventions would not have been
carried out by a more experienced misoprostol provider.
Given that most interventions were carried out in the
early stages of the study, providers may also have beenl Surgical RR (95% CI) /
p-valuen = 374
100.0 (374) 0.90 (0.88-0.92)
0.0 (0)
) 100.0 (100/100) 0.89 (0.84-0.94)
) 100.0 (81/81) 0.85 (0.78-0.92)
) 100.0 (61/61) 0.87 (0.81-0.94)
) 100.0 (25/25) 0.92 (0.85-0.99)
1) 100.0 (107/107) 0.97 (0.97-0.97)
7) 17.8 (60/338) p < 0.001
) 18.6 (16/86) p < 0.001
) 17.5 (44/252) p < 0.01
) 1.1 (4/366) p = 0.14
) 1.1 (4/364) p < 0.01
d 6 in the surgical arm.
n the surgical arm.
1 unscheduled visit.
Table 3 Side-effects: % (n)*
Misoprostol Surgical p-value
n = 465 n = 374
Severity of side effects
“None” 14.8 (65/440) 24.0 (53/221) 0.02
“Easily tolerable” / “tolerable” 77.5 (341/440) 71.0 (157/221)
“Severe” / “very severe” 7.7 (34/440) 5.0 (11/221)
Normal bleeding** 35.4 (119/336) 9.4 (17/180) < 0.001
Heavy bleeding** 11.6 (39/336) 0.6 (1/180) < 0.001
Spotting*** 31.0 (104/336) 51.1 (92/180) < 0.001
Pain/cramps** 54.8 (184/336) 24.4 (44/180) < 0.001
Fever/chills** 3.9 (13/336) 1.7 (3/180) 0.20
Nausea** 16.7 (56/336) 2.8 (5/180) < 0.001
Vomiting** 7.1 (24/336) 1.1 (2/180) < 0.01
Headache† 7.7 (26/336) 8.9 (16/180) 0.74
Gastrointestinal issues† 15.2 (51/336) 3.9 (7/180) < 0.001
Vertigo† 1.2 (4/336) 4.4 (8/180) 0.03
Tolerability of pain**
“No pain” 5.1 (17/332) 5.6 (10/177) < 0.01
“Very tolerable” / “tolerable” 92.2 (306/332) 85.3 (151/177)
“Not tolerable” 2.7 (9/332) 9.0 (16/177)
Difficulty of treatment*** 0.45
“Not at all difficult” / “a little difficult” 95.4 (290/304) 97.4 (148/152)
“Difficult” / “very difficult” 4.6 (14/304) 2.6 (4/152)
Acceptability of bleeding**
“Acceptable” / “very acceptable” 99.1 (328/331) 100.0 (174/174) 0.56
“Not acceptable” 0.9 (3/331) 0.0 (0/0)
*Denominators vary due to response rate for each question.
**Data only collected in Senegal, Nigeria, and Burkina Faso.
***Data only collected in Senegal and Burkina Faso.
†Listed in “other” side effects; only collected in Senegal, Nigeria, and Burkina Faso.
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lack of comfort may have translated to women’s unease
with the process. Indeed, it is not uncommon to see suc-
cess rates improve over time when misoprostol is first
introduced; providers who have not previously used mis-
oprostol for treating incomplete abortion (or for medical
abortion) need to become accustomed to the process,




“Satisfactory” / “very satisfactory” 98.5 (452/
“Unsatisfactory” / “very unsatisfactory” 1.5 (7/45
Would select this method again, if needed 97.6 (448/
Would recommend this method to a friend 97.6 (448/
*Denominators vary due to response rate for each question.intervene prematurely. For example, in a recent study of
misoprostol for incomplete abortion in Ghana [9], all
failures occurred in the first half of the study (J. Taylor,
personal communication, September 20, 2011). In
Turkey, a study with a low rate of success with medical
abortion was followed by a second study with a much
higher completion rate after more extensive provider
education and experience were provided [10,11]. And instol Surgical p-value
5 n = 374
459) 98.1 (314/320) 0.78
9) 1.9 (6/320)
459) 87.8 (274/312) < 0.001
459) 85.8 (271/316) < 0.001
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both at the beginning of the study and overall, and was
the only country to have previous experience with the
method. This pattern suggests that when introducing
misoprostol into new settings, additional focus should
be placed on provider training as well as on provider
follow-up and support to ensure that clinicians are fully
comfortable with both the amount and duration of side
effects, especially bleeding.
As in many studies addressing abortion and/or post-
abortion care in settings with limited legal access to safe
abortion care, some women were lost to follow-up. High
rates of loss to follow-up are common with incomplete
abortion treatment, particularly where cost and distance
to care are substantial factors, as well as in settings
where abortion is illegal [2,5]. Moreover, cultural norms
in some settings discourage seeking care when it is not
necessary, suggesting that women with complications
are more likely to return and those not returning are
more likely to have had no further problems [5]. One
proposed solution to poor in-clinic follow-up is to de-
velop an at-home assessment tool with a symptom
checklist to help women determine whether or not they
need to return for further care [2]. Telephone follow-up
could also be established to reduce the need for in-
person assessment [12].
While the sites in this study were all secondary and
tertiary level hospitals, the findings suggest a great po-
tential for use of misoprostol at lower-level facilities
where physicians are less available. As demonstrated in 4
of the 6 sites, physicians are not needed to provide PAC
services: both counseling and provision of the medica-
tions were successfully provided by other clinicians such
as nurses or midwives trained in treatment protocols.
However, more attention to training in how to avoid un-
necessary intervention would be beneficial. The option
of a first line treatment at out-patient clinics could re-
duce the burden on higher-level settings where case
loads are high and also increase access for women who
may have difficulties reaching higher level care. This
would facilitate task shifting and reduce the human re-
source burden in many countries.
This study supports previous research showing that
ultrasound is not necessary for outcome assessment when
treating incomplete abortion with misoprostol [13-15].
The majority of misoprostol cases were successfully eval-
uated without the use of ultrasound. And in Senegal,
where ultrasound use was required, its use decreased
substantially over the course of the study (as providers
likely became more comfortable with the process), and
clinicians relied more on clinical assessment alone. Mis-
oprostol may be very appropriate in places where ultra-
sound is not available and/or where providers are not
trained in ultrasound use.There were limitations to this study including small
sample size across different sites, the mandated use of
ultrasound in Senegal, and the differences in standard of
care at each location. However, regardless of these lim-
itations, this research gives us a good overview of what
service provision of misoprostol for treatment of incom-
plete abortion might be like in these settings.
Conclusion
The evidence is substantial and quite clear that miso-
prostol can be used safely, successfully, and satisfactorily
for treatment of incomplete abortion. This observation
is particularly important for locations where surgical
interventions are less available and/or less acceptable.
During the course of this study, the World Health
Organization added misoprostol for incomplete abortion
to their essential medicines list (EML) [16]. With the
established success of both oral and sublingual routes,
there are two viable misoprostol options for PAC ser-
vices. In low-resource settings these protocols are critical
for moving forward. Focus now needs to shift to pro-
gram development and implementation, including more
extensive provider training and assurance of drug avail-
ability. Programs created to translate the research into
practice are critical to realize the potential for this tech-
nology to improve women’s health.
Endnotes
aMauritania: The Allendale Investigational Review
Board; Niger: Ministry of Health Ethical Review Board;
Senegal: National Counsel on Health Research, National
Ethical Committee, Ministry of Health and Prevention;
Burkina Faso: Burkina Faso Ministry of Health Ethical
Review Board; Nigeria: Ethical Committee of the College
of Medicine and the University of Ibadan/University
College Hospital.
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